RecruitingNCT05263570

The Efficiency for Stage II-III HR+/HER2+ Early Breast Cancer Patient With Standard Neoadjuvant Therapy in Real World.

The Efficiency for Patient With Stage II-III HR+/HER2+ Early Breast Cancer With Standard Neoadjuvant Therapy: a Retrospective, Multicenter Study in Real World Settings.

Sponsor

Shengjing Hospital

Enrollment

200 participants

Start Date

Aug 1, 2022

Study Type

OBSERVATIONAL

Conditions

Breast Cancer

Summary

To observe the efficiency for patient with stage II-III HR+/HER2+ early breast cancer with standard neoadjuvant therapy, a retrospective, multicenter study in real world settings.

Eligibility

Sex: FEMALEMin Age: 18 Years

Inclusion Criteria6

Age ≥18 years or older
HR+/HER2- breast cancer diagnosis based on local standards
Women having stage II-III breast cancer diagnosed based on AJCC cancer staging system (8th edition) who will be admitted because of breast cancer for the first time
Standard Therapy, determined at the discretion of the investigator, including （TCbHP/THP/EC-THP/AC-THP）
Complete medical history was available
Karnofsky Performance Status (KPS) Scale score ≥ 70

Exclusion Criteria4

Women who have received any form of anti-tumor treatment - (chemotherapy, radiotherapy, molecular targeted therapy, or endocrine therapy)
Pregnant or breast-feeding women
Those who have bilateral breast cancer, inflammatory breast cancer or occult breast cancer
Those who have stage IV breast cancer